Combination therapy for hematological malignancies

摘要

Disclosed is a method of treating a T-cell lymphoma, said method comprising administering to a patient in need of such treatment a therapeutically effective amount of an HDAC inhibitor and a therapeutically effective amount of an alkylating agent. Preferred combination is romidepsin and bendamustine (4-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid).